At DFE Pharma, we have embedded sustainability into our corporate strategy. Our environmental, social and governance (ESG) commitments strengthen our partners’ sustainability credentials and drive positive change for both people and the planet. Guided by our purpose: “Your medicines, our solutions. Moving to a healthier world”, we strive to make a difference every day, everywhere.
In 2024, we continued our journey to build upon the solid foundation of our ESG program. Our advances in sustainability can be found in our ESG Report 2024, which includes highlights such as:
- Awarded the EcoVadis Gold Medal, recognizing our position in the top 5% of all rated companies worldwide, with scores above the industry average in all four assessed areas: Environment, Labor and Human Rights, Ethics and Sustainable Procurement.
- Science-Based Targets initiative (SBTi) approval of our near-term and FLAG targets. This approval validates that our ambitious and scientifically grounded commitment to reducing greenhouse gas emissions is in line with limiting the global average temperature increase to 1.5ºC above pre-industrial levels.
- 100% Green electricity now used at all EU sites.
- Assessed 100% of our suppliers (based on external spend) for Corporate Social Responsibility risks using EcoVadis IQ Plus, reinforcing our commitment to responsible sourcing and sustainable supply chain practices.
For our customers and their patients, now and in the future, our vision is to remain a global leader in sustainable and future-proof excipients.